López L, Martínez V, Ramos GA, Arias GAC, Champet LAM

Language: Spanish
References: 19
Page: 206-216
PDF size: 189.13 Kb.

ABSTRACT

Dermatomyositis is a systemic disorder of unknown cause whose principal manifestations are muscle weakness and skin disease. The peak incidence is in the fifth and sixth decades of life. The clinically suspected diagnosis is confirmed by examining the serum muscle enzymes, electromyography findings, and muscle biopsy. Most patients respond to corticosteroids.

REFERENCES

1. Londońo AM. Dermatomiositis. Piel 2005; 6: 174-182.

2. Kovacs S, Kovacs SC. Dermatomyositis. J Am Acad Dermatol 1998; 39: 899-920.

3. Sontheimer RD, Costner MI. Dermatomyositis. Freedberg I, Eisen A, Wolf K, Arsten K, Goldsmith L, Katz S, et al, editors. Fitzpatrick´s Dermatology in General Medicine. 6th ed. Mc Graw-Hill, 2003; p.1694-1707.

4. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344-7.

5. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 403-7.

6. Hachulla E. Dermatomyositis and polymyositis: clinical aspects and treatment. Ann Med Intern 2001; 152: 455-64.

7. Gallais V, Crickx B, Belaich S. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. Ann Dermatol Venereol 1996; 123: 722-6.

8. Leon G, Blancas F. Dermatomiositis. PAC Dermatología, 1a ed. Intersistemas, 2001:21-24.

9. Parodi A, Caproni M, Marzano AV et al. Dermatomyositis in 132 patients with different clinical subtypes; cutaneous signs, constitutional symptoms and circulating antibodies. Acta Derm Venereol 2002; 82: 48-51.

10. Hann T, Newman E. Juvenile dermatomyositits. A retrospective review of 30 year experience. J Am Acad Dermatol 2001; 45: 28-34.

11. Sontheimer R. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002; 46: 626-36.

12. Caproni M, Cardinali C et al. Amyopathic dermatomyositis: a review by the Italian Group of Immunodermatology. Arch Dermatol 2002; 138: 23-7.

13. Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymiositis: a case-control study. Br J Dermatol 2001; 144: 825-31.

14. Hill CL, Zhang Y et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population–based study. Lancet 2001; 357: 96-100.

15. Dalakas M, Honfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362: 971-82.

16. Dalakas Mc, Illa I et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment of Dermatomyositis. N Engl J Med 1993; 329: 1993-2000.

17. Peake MF, Perkins P et al. Cutaneous ulcers of refractory polymyositis responsive to intravenous immunoglobulin. Cutis 1998; 62: 89-93.

18. Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an affective corticosteroid-sparing gent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol 1997; 36: 67-71.

19. Ichiki Y, Akiyama T et al. An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem. Br J Dermatol 2001; 144: 894-7.